We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Cancer Researchers Identify Factors That Drive Melanoma Metastasis

By LabMedica International staff writers
Posted on 23 Feb 2017
Print article
Image: A laboratory-generated melanoma tumor (Photo courtesy of Dr. Aaron Smith, Queensland University of Technology).
Image: A laboratory-generated melanoma tumor (Photo courtesy of Dr. Aaron Smith, Queensland University of Technology).
Cancer researchers have traced a molecular pathway that cycles melanoma cells between modes that favor growth of the primary tumor (progression) and modes that favor invasion of other parts of the body (metastasis).

Cancer is characterized by uncontrolled growth of cells, but if uncontrolled growth was the only problem then cancer cells would be easily treated with surgery in most cases. What makes cancer deadly is its tendency to invade tissue and migrate to other regions of the body. Metastatic melanoma is one of the most aggressive and difficult to treat of all cancer types.

Melanoma is a heterogeneous cancer, made up of many cellular populations that differ in their ability to induce tumor growth or invasion throughout the body. These populations have been found to switch back and forth to drive invasion and progression. This process appears to be controlled by opposing action of two genes, MITF (Microphthalmia-associated transcription factor) and BRN2 (POU class 3 homeobox 2).

Investigators at Queensland University of Technology reported in a paper published in the January 14, 2017, online edition of the journal EBiomedicine that the NFIB (nuclear factor I B) transcription factor was a novel downstream effector of BRN2 function in melanoma cells linked to the migratory and invasive characteristics of these cells. Furthermore, the function of NFIB appeared to drive an invasive phenotype through an epigenetic mechanism achieved via the upregulation of the polycomb group protein EZH2 (Enhancer of zeste homolog 2).

"BRN2 function reduces MITF expression to slow down proliferation and put the cells into invasive mode," said senior author Dr. Aaron Smith, lecturer in the school of biomedical science at Queensland University of Technology. "Our project has identified a pathway that allows BRN2 to do this, firstly by increasing the expression of another regulatory factor called NFIB that further controls an invasive program in these cells."

"An important target of NFIB is an enzyme called EZH2 which then produces global (wide ranging) changes to the cells activity. EZH2 favors the expression of invasive genes and also turns "off" MITF to prevent proliferation, further re-enforcing the invasive capability of the tumor cells", said Dr. Smith. "We have evidence the NFIB-EZH2 pathway may also underpin metastasis of other cancer types as well such as lung cancer. The good news is there are drugs to chemically inhibit EZH2 which are already in pre-clinical trials and which could be used to block the invasion."

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
One Step HbA1c Measuring System
GREENCARE A1c
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.